08:54 AM EDT, 06/05/2025 (MT Newswires) -- Kazia Therapeutics ( KZIA ) said Thursday that the first patient had been dosed in a phase 1 trial evaluating its experimental drug, paxalisib, in combination with olaparib or pembrolizumab for patients with advanced breast cancer.

The company said the multi-center, open-label trial would assess the safety, tolerability, and early efficacy of paxalisib-based combinations, adding that it also includes biomarker profiling to guide future development.